Article information
Full text is only available in PDF
Bibliografía
[1.]
J.P. Callen.
Dermatomyositis.
Lancet, 355 (2000), pp. 53-57
[2.]
I. Caro.
Dermatomyositis.
Semin Cutan Med Surg, 20 (2001), pp. 38-45
[3.]
M.C. Dalakas, R. Hohlfeld.
Polymyositis and dermatomyositis.
Lancet, 362 (2003), pp. 971-982
[4.]
R.D. Sontheimer.
Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis.
Curr Opin Rheumatol, 11 (1999), pp. 475-482
[5.]
Y.S. Dai, H.C. Chiu.
Periorbital heliotrope oedema as the only initial clinical manifestation of systemic lupus erythematosus in a primigravida.
Br J Dermatol, 143 (2000), pp. 679-680
[6.]
A. Parodi, M. Caproni, A.V. Marzano, C. De Simone, M. La Placa, P. Quaglino, et al.
Dermatomyositis in 132 patients with different clinical subtypes: cutaneous signs, constitutional symptoms and circulating antibodies.
Acta Derm Venereol, 82 (2002), pp. 48-51
[7.]
M. Caproni, C. Cardinali, A. Parodi, B. Giomi, M. Papini, M. Vaccaro, et al.
Amyopathic dermatomyositis: a review by the Italian Group of Immunodermatology.
Arch Dermatol, 138 (2002), pp. 23-27
[8.]
B. Santmyire-Rosenberger, E.M. Dugan.
Skin involvement in dermatomyositis.
Curr Opin Rheumatol, 15 (2003), pp. 714-722
[9.]
T.Y. Woo, J.P. Callen, J.J. Voorhees, D.R. Bickers, R. Hanno, C. Hawkins.
Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine.
J Am Acad Dermatol, 10 (1984), pp. 592-600
[10.]
J.S. Kasteler, J.P. Callen.
Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis.
J Am Acad Dermatol, 36 (1997), pp. 67-71
[11.]
M.C. Dalakas.
High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials.
Neurol Sci, 24 (2003), pp. S256-S259
Copyright © 2005. Elsevier España S.L. Barcelona
